A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

Bibliographic Details
Main Authors: Carlo, Maria I., Molina, Ana M., Lakhman, Yulia, Patil, Sujata, Woo, Kaitlin, DeLuca, John, Lee, Chung-Han, Hsieh, James J., Feldman, Darren R., Motzer, Robert J., H. Voss, Martin
Format: Online
Language:English
Published: AlphaMed Press 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943396/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943396/

Similar Items